Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Saskia, Nederend, Maaike, Jansen, J.H. Marco, Reiding, Karli R., Jacobino, Shamir R., Meeldijk, Jan, Bovenschen, Niels, Wuhrer, Manfred, Valerius, Thomas, Ubink, Ruud, Boross, Peter, Rouwendal, Gerard, Leusen, Jeanette H.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966554/
https://www.ncbi.nlm.nih.gov/pubmed/26466856
http://dx.doi.org/10.1080/19420862.2015.1106658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966554/
https://www.ncbi.nlm.nih.gov/pubmed/26466856
http://dx.doi.org/10.1080/19420862.2015.1106658

Ejemplares similares